Evidence map›Paper›PMID 39980202›Full record

ArticleJournal of chemical information and modeling2025

GRADE and X-GRADE: Unveiling Novel Protein-Ligand Interaction Fingerprints Based on GRAIL Scores.

Christian Fellinger, Thomas Seidel, Benjamin Merget, Klaus-Juergen Schleifer, Thierry Langer

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christian FellingerDepartment of Pharmaceutical Sciences, Faculty of Life Scences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
Thomas SeidelDepartment of Pharmaceutical Sciences, Faculty of Life Scences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0002-9815-6577
Benjamin MergetBASF SE, Carl-Bosch-Strasse 38, 67056 Ludwigshafen am Rhein, Germany.
Klaus-Juergen SchleiferBASF SE, Carl-Bosch-Strasse 38, 67056 Ludwigshafen am Rhein, Germany.ORCID 0000-0003-3428-1384
Thierry LangerDepartment of Pharmaceutical Sciences, Faculty of Life Scences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0002-5242-1240

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nonbonding molecular interactions, such as hydrogen bonding, hydrophobic contacts, ionic interactions, etc., are at the heart of many biological processes, and their appropriate treatment is essential for the successful application of numerous computational drug design methods. This paper introduces GRADE, a novel interaction fingerprint (IFP) descriptor that quantifies these interactions using floating point values derived from GRAIL scores, encoding both the presence and quality of interactions. GRADE is available in two versions: a basic 35-element variant and an extended 177-element variant. Three case studies demonstrate GRADE's utility: (1) dimensionality reduction for visualizing the chemical space of protein-ligand complexes using Uniform Manifold Approximation and Projection (UMAP), showing competitive performance with complex descriptors; (2) binding affinity prediction, where GRADE achieved reasonable accuracy with minimal machine learning optimization; and (3) three-dimensional-quantitative structure-activity relationship (3D-QSAR) modeling for a specific protein target, where GRADE enhanced the performance of Morgan Fingerprints.

Indexed as

ProteinsDrug DesignLigandsMachine LearningModels, MolecularProtein BindingQuantitative Structure-Activity RelationshipLigandsProteins

Identifiers

PMID39980202
PMCPMC11898076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.